ArticleProbiotics and antimicrobial proteins2026
Alginate-Grape Pomace Flour Microcapsules for Enhanced Protection and Delivery of Lacticaseibacillus rhamnosus GG.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incorporation of plant-derived fibers as co-encapsulating agents has emerged as a strategy to improve probiotic stability and functionality. This study evaluated grape pomace flour (GF) as a co-encapsulant in sodium alginate (SA) based microcapsules containing Lacticaseibacillus rhamnosus GG, focusing on structural properties, thermal resistance, antioxidant activity, gastrointestinal survival, and viability in orange juice. High encapsulation efficiencies were obtained for alginate (94.80%) and alginate-GF systems (91.13%), with viable counts above 8.3 log CFU/mL. FTIR, DSC, and TGA analyses demonstrated molecular interactions between alginate and GF, resulting in modified thermal transitions and enhanced matrix cohesion. SA/GF microcapsules showed improved refrigerated stability, maintaining ≥ 8.0 log CFU/mL after 28 days at 4 °C, whereas free cells declined to 3.3-4.0 log CFU/mL. During rapid pasteurization (72 °C/15 s), SA/GF capsules preserved 11 log CFU/g, compared to 7.15 log CFU/g in alginate-only capsules, while free cells were completely inactivated. Under simulated gastric conditions, SA/GF capsules maintained 8.60-9.19 log CFU/g, whereas alginate-only capsules decreased to 5.94 log CFU/g after 90 min, and free cells became undetectable after 120 min. In simulated intestinal juice, SA/GF capsules recovered to 9.45 log CFU/g at 120 min. In orange juice, free cells showed > 2.5 log reduction within 3 days, while encapsulated formulations exhibited reductions < 1 log over 9 days (p ≤ 0.05). Overall, GF reinforced the alginate matrix, reduced microbial inactivation, and improved probiotic resistance and survival, supporting its application as a sustainable co-encapsulant in functional foods.
Indexed as
Identifiers
42809175What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.